Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
BIIB News
Ionis stock jumped Thursday after a Food and Drug Administration panel offered a mixed view of its Biogen (BIIB)-partnered treatment for a deadly neurodegenerat...
Tempe, AZ --News Direct-- By Rachael Green, Benzinga Interested in investing in iMetabolic BioPharma? Click here to get started! iMetabolic BioPharma (iMBP)...
The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 9 yes - 0 no, indicating sufficient evidence showing a reduction in plasma neurof...
Analyst ratings
63%
of 32 ratingsBIIB Earnings
More BIIB News
Biogen Inc. SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEW...
Biogen Inc. BIIB, -1.85% received a setback late Wednesday after a Food and Drug Administration advisory committee said the biotech drug maker’s proposed amyotr...
Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session. This change lagged the S&P 500's 1.3% gain on...
It appears likely that a new drug to treat amyotrophic lateral sclerosis (ALS) will get approval in the U.S. Regulators shared their thinking ahead of an adviso...
FDA's Peripheral and Central Nervous System Drugs Advisory Committee will virtually meet on Wednesday, March 22, to discuss Biogen Inc's (NASDAQ: BIIB) ALS drug...
March 20 (Reuters) - The U.S. health regulator's staff said on Monday safety issues with Biogen Inc's (BIIB.O) drug to treat an ultra-rare form of...
By Josh Beckerman Sangamo Therapeutics Inc. shares were down 8% to $1.84 after hours as the company said Novartis AG and Biogen Inc. terminated collaboration a...
